Mitsubishi UFJ Asset Management Boosts Stake in Cooper Companies

The investment firm increased its holdings in the medical device company by 3.7% in the third quarter.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.7% in the 3rd quarter, according to the company's recent 13F filing with the Securities and Exchange Commission. The firm now owns 398,052 shares of the medical device company's stock, valued at approximately $27,290,000.

Why it matters

The increase in Mitsubishi UFJ Asset Management's stake in Cooper Companies reflects the investment firm's confidence in the medical device company's growth potential. Cooper Companies is a major provider of vision care and women's health products, operating through its CooperVision and CooperSurgical segments.

The details

According to the 13F filing, Mitsubishi UFJ Asset Management acquired an additional 14,316 shares of Cooper Companies during the third quarter, bringing its total ownership to approximately 0.20% of the company's outstanding shares. The investment firm's increased stake in Cooper Companies comes as the medical device company has seen its stock price fluctuate in recent months, with shares trading between $61.78 and $92.84 over the past year.

  • Mitsubishi UFJ Asset Management increased its stake in Cooper Companies during the 3rd quarter of 2025.

The players

Mitsubishi UFJ Asset Management Co. Ltd.

An investment management firm that is a subsidiary of Mitsubishi UFJ Financial Group, one of the largest financial institutions in the world.

The Cooper Companies, Inc.

A global medical device company that develops, manufactures, and markets a broad range of soft contact lenses and related accessories, as well as women's health products.

Got photos? Submit your photos here. ›

The takeaway

Mitsubishi UFJ Asset Management's increased stake in Cooper Companies reflects the investment firm's confidence in the medical device company's long-term growth prospects, particularly in its core vision care and women's health product lines.